Executive Director
Immunologix Laboratories
Tampa, Florida
As co-founder of the Translational Sciences Division, Dr. Devangi Mehta builds partnerships directly with clients to provide translational strategies, facilitate regulatory engagements and deliver the assays, datasets, and integrated analyses to advance their drug development programs. Devangi received her Ph.D. from Harvard University and subsequently through extensive experience in drug development at both large and small biotech and pharma has built a reputation as an internationally recognized thought leader in translational sciences. She has led multiple scientific teams responsible for developing and executing stage-appropriate biomarker and bioanalytical strategies that support internal program decision-making, regulatory submissions, post-marketing, and drug-positioning goals. She brings more than 18 years of drug development experience, with deep expertise in designing integrated biomarker and bioanalytical strategies as well as developing PK, immunogenicity, and biomarker assays to support drug programs from discovery to post-market and spanning multiple disease indications. Externally, Devangi has special interests in advancing industry-wide best practices for assay development and “fit-for-purpose” validation of ligand-binding and flow cytometry biomarker assays. She is an invited speaker at multiple biomarker and bioanalytical conferences, contributor to industry white papers, and has numerous publications of her translational and medical research in peer reviewed journals.
Disclosure information not submitted.
Rapid Fire: High Content Bioanalysis
Thursday, May 16, 2024
2:00 PM – 3:00 PM PT